|1.||Langhans, Wolfgang: 3 articles (01/2010 - 01/2003)|
|2.||von Meyenburg, Claudia: 2 articles (03/2003 - 01/2003)|
|3.||Hrupka, Brian J: 2 articles (03/2003 - 01/2003)|
|4.||Jonaidi, Hosein: 1 article (09/2012)|
|5.||Taati, Majid: 1 article (09/2012)|
|6.||Amini, Elham: 1 article (09/2012)|
|7.||Zendehdel, Morteza: 1 article (09/2012)|
|8.||Asarian, Lori: 1 article (01/2010)|
|9.||Kopf, Brigitte S: 1 article (01/2010)|
|10.||Geary, Nori: 1 article (01/2010)|
01/08/2010 - "SB 242084 markedly attenuated the LPS-induced reduction in food intake, with no anorexia evident for the first 2 h after LPS. "
09/01/2012 - "In addition, 5-HT-induced anorexia was significantly attenuated by DL-AP5 pretreatment (P < 0.05), while SB 242084 had no effect on glutamate-induced hypophagia. "
01/08/2010 - "Here we used the selective, potent and brain-penetrant serotonin 2C-receptor antagonist SB 242084 to identify the brain sites involved in LPS anorexia. "
01/01/2003 - "In contrast, both ritanserin (5-HT(2A/C)-receptor antagonist) (0.5 mg/kg BW) and SB 242084 (5-HT(2C)) (0.3 mg/kg BW) attenuated LPS-induced anorexia at doses that did not alter food intake in non-LPS-treated rats (all P<.01). "
09/01/2012 - "Food intake was measured in chickens after centrally administered lipopolysaccharide (LPS) (20 ng) (0 h), followed by intracerebroventricular (ICV) injection of the 5-HT(1A) autoreceptor agonist (8-OH-DPAT, 61 nmol), 5-HT(2c) receptor antagonist (SB 242084, 30 nm), and NMDA receptor antagonist (DL-AP5, 5 nm) at the onset of anorexia (4 h). "
07/01/2002 - "In contrast to SB-242084, the selective 5-HT(2A)R antagonist R93274 as well as the non-selective 5-HT(2A)R antagonists (R99647, ketanserin, risperidone, pipamperone and mianserin) significantly inhibited tryptamine-induced forepaw treading and tremors, and reversed peripherally mediated cyanosis into hyperaemia; only the 5-HT(2A/C)R antagonists R99647 and mianserin inhibited the tryptamine-induced hunched back. "
09/01/2003 - "Furthermore, combined blockade of H1 and 5-HT2C receptors (SB 242084 and mepyramine) was also insufficient to produce hyperphagia. "
09/01/2003 - "To examine the possible contribution of serotonin (5-HT) and histamine (H) receptor blockade in antipsychotic-associated hyperphagia, rats were trained to drink a palatable, high-calorie fat emulsion (10% intralipid) during 30-min sessions and were tested following pretreatment with mepyramine (H1 receptor antagonist), metergoline (5-HT(1/2) receptor antagonist), cyproheptadine (H1 and 5-HT(2A/2B/2C) and muscarinic receptor antagonist), SB 242084 (5-HT2C receptor antagonist) and an SB 242084-mepyramine combination. "
|1.||5-HT2C Serotonin Receptor
|3.||Serotonin (5 Hydroxytryptamine)
|5.||Interleukin-1beta (Interleukin 1 beta)
|7.||Risperidone (Risperdal Consta)
|8.||Glutamic Acid (Glutamate)